tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

DENTSPLY SIRONA: Hold Rating Amid Strong Earnings, Leadership Changes, and Market Challenges

DENTSPLY SIRONA: Hold Rating Amid Strong Earnings, Leadership Changes, and Market Challenges

DENTSPLY SIRONA, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Erin Wright from Morgan Stanley maintained a Hold rating on the stock and has a $14.00 price target.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Erin Wright has given his Hold rating due to a combination of factors affecting DENTSPLY SIRONA’s performance. The company’s second-quarter earnings per share exceeded expectations, driven by higher revenues and profitability. However, this positive performance was partially offset by below-the-line items, such as other expenses and taxes, which impacted the overall financial results.
Despite maintaining its guidance for 2025, including EPS and organic revenue growth targets, the company faces challenges in the U.S. market, where organic revenue pressure was notably high. Additionally, there have been significant leadership changes, with a new CEO and CFO, which may influence the company’s strategic direction. These mixed signals, along with the need for more clarity on factors like foreign exchange and tariffs, contribute to the Hold rating, as the company navigates a challenging dental market environment.

In another report released yesterday, Leerink Partners also maintained a Hold rating on the stock with a $17.00 price target.

XRAY’s price has also changed moderately for the past six months – from $18.760 to $13.230, which is a -29.48% drop .

Disclaimer & DisclosureReport an Issue

1